MX2021005334A - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
MX2021005334A
MX2021005334A MX2021005334A MX2021005334A MX2021005334A MX 2021005334 A MX2021005334 A MX 2021005334A MX 2021005334 A MX2021005334 A MX 2021005334A MX 2021005334 A MX2021005334 A MX 2021005334A MX 2021005334 A MX2021005334 A MX 2021005334A
Authority
MX
Mexico
Prior art keywords
compounds
atopic dermatitis
pruritus
chemical compounds
inhibitors
Prior art date
Application number
MX2021005334A
Other languages
English (en)
Inventor
Joe B Perales
Weiming Fan
Jason D Speake
Bharathi Pandi
Original Assignee
Avista Pharma Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avista Pharma Solutions Inc filed Critical Avista Pharma Solutions Inc
Publication of MX2021005334A publication Critical patent/MX2021005334A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención describe compuestos novedosos, o sus sales farmacéuticamente aceptables, composiciones farmacéuticas que los contienen y sus usos médicos. Los compuestos de la invención tienen actividad como inhibidores de Janus Cinasa y son útiles en el tratamiento o control de prurito, asociado con dermatitis alérgica, dermatitis atópica en animales, y otros trastornos e indicaciones donde sería deseable inmunosupresión/inmunomodulación . En la presente también se describen métodos para tratar prurito y dermatitis atópica mediante la administración de los compuestos de la invención, que son inhibidores de JAK 1.
MX2021005334A 2018-11-05 2019-11-04 Compuestos quimicos. MX2021005334A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755679P 2018-11-05 2018-11-05
PCT/US2019/059634 WO2020096948A1 (en) 2018-11-05 2019-11-04 Chemical compounds

Publications (1)

Publication Number Publication Date
MX2021005334A true MX2021005334A (es) 2021-06-23

Family

ID=70458378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005334A MX2021005334A (es) 2018-11-05 2019-11-04 Compuestos quimicos.

Country Status (11)

Country Link
US (1) US10744136B2 (es)
EP (1) EP3877389A4 (es)
JP (1) JP2022506682A (es)
KR (1) KR20210072125A (es)
CN (1) CN113272306A (es)
AU (1) AU2019375412A1 (es)
BR (1) BR112021008742A2 (es)
CA (1) CA3118488A1 (es)
CL (1) CL2021001177A1 (es)
MX (1) MX2021005334A (es)
WO (1) WO2020096948A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101643514B1 (ko) 2007-07-09 2016-07-27 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
RU2009140319A (ru) 2007-04-02 2011-05-10 Палау Фарма С.А. (Es) Производные пирролпиримидина
CA2733359C (en) * 2008-08-20 2014-08-05 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
ME02904B (me) * 2013-02-22 2018-04-20 Pfizer DERIVATI PIROLO[2,3 -d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK)
WO2014194741A1 (zh) * 2013-06-07 2014-12-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐及其制备方法
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
EP3768272A4 (en) * 2018-03-21 2021-08-11 Xibin Liao JAK INHIBITORS

Also Published As

Publication number Publication date
WO2020096948A1 (en) 2020-05-14
US10744136B2 (en) 2020-08-18
BR112021008742A2 (pt) 2021-08-10
EP3877389A4 (en) 2022-07-13
CA3118488A1 (en) 2020-05-14
CN113272306A (zh) 2021-08-17
EP3877389A1 (en) 2021-09-15
US20200138811A1 (en) 2020-05-07
KR20210072125A (ko) 2021-06-16
AU2019375412A1 (en) 2021-06-03
JP2022506682A (ja) 2022-01-17
CL2021001177A1 (es) 2022-05-27

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2020002806A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso.
MX2018006223A (es) Moduladores de ror-gamma.
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
PH12021550872A1 (en) Therapeutic compounds
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MY201535A (en) Therapeutic compounds
EP4233913A3 (en) Improved bromocriptine formulations
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2020006174A (es) Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
MX2020006228A (es) Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018008272A (es) Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.
MX2021004860A (es) Piridazinas novedosas.
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis